Sunitinib side effects as surrogate biomarkers of efficacy

Christian Kollmannsberger

Abstract


With the proliferation of treatment options for the management of metastatic renal cell carcinoma (mRCC) over the past decade, predictive markers of response to therapy are becoming increasingly important. Sunitinib is commonly used in the first-line treatment of mRCC. Common mechanism-based adverse events, including hypertension, hypothyroidism, hand-foot syndrome, and neutropenia, have been explored as potential biomarkers of the clinical efficacy of sunitinib in mRCC and are reviewed in this article.

Full Text:

PDF


DOI: http://dx.doi.org/10.5489/cuaj.4315